Skip to main content

Aviva Systems Biology, Applied Biosystems, Agilent


Aviva Systems Biology last week launched its ChIP-GLAS system, which the company claims can simultaneously detect 20,000 human promoters from a single sample, and should be useful for researchers conducting gene transcription studies.

The San Diego-based company said the first stage launch of the system includes both 10K and 20K ChIP-GLAS microarrays, as well as a supporting kit for users.

Applied Biosystems last week introduced its Advanced Gene Expression Service Provider Program to encourage service providers to use its Expression Array System and TaqMan assays for gene expression-analysis offerings.

The company said it is offering a product bundle around its Expression Array System — which includes human, rat, and mouse arrays, as well as technical and promotional support, and options for including additional products such as TaqMan assays and RT-PCR systems.

Agilent this week released its Literature Search tool, an automated tool for the multidisciplinary study of biological systems. The tool is available as a free plug-in to Cytoscape 2.1, an open-source bioinformatics platform that enables researchers to form a visual map of complex biological networks, increasing their understanding of molecular pathways and the biological causes of disease.

According to Agilent, the tool searches for and extracts information from multiple textual databases, such as those of the US Patent Office and the National Center for Biotechnology Information. The plug-in pulls information from these sources and represents it within Cytoscape as a map of the relationships between the biological entities, such as genes and proteins for the users convenience.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.